Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

China’s 3rd Annual Asia Scientific Congress programs feature latest updates on cancer

In an effort to curb the cancer rates, the country has adopted evidence-based treatment guidelines and continues to strengthen a number of strategic collaborations with the National Comprehensive Cancer Network® (NCCN®) as demonstrated by several NCCN programs scheduled throughout China this spring.

25 Mar 2010

Agendia brings new personalized treatment for breast cancer patients

Agendia, a world leader in molecular cancer diagnostics, today announced that its breast cancer product offering, consisting of breast cancer recurrence test MammaPrint(R), and TargetPrint(TM), has been expanded with BluePrint (TM) to report important additional information on tumor subtypes.

24 Mar 2010

Fertility remains a significant issue for majority of breast cancer patients

The use of chemotherapy and hormonal treatments in young women can have significant implications for their fertility.

24 Mar 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

PPD introduces comprehensive laboratory services for vaccine and biologic drug development

PPD, Inc. (Nasdaq: PPDI) today announced it is launching the PPD Vaccines & Biologics Center of Excellence, a first-in-kind comprehensive network of integrated, world-class laboratory services focused specifically on vaccine and biologic drug development.

24 Mar 2010

Patients and doctors' views on important endpoints in incurable metastatic breast cancer

Many patients with metastatic breast cancer believe that the primary goal in survival with new treatment should be to prolong life by at least a year over the survival they might expect from using current best therapies, a researcher will tell the seventh European Breast Cancer Conference in Barcelona today. This finding contrasts with doctors' perception that an additional four to six months' survival is significant enough to consider a new treatment worthwhile.

24 Mar 2010

Life Technologies' real-time PCR instrument available for IVD use in Europe

Life Technologies Corporation (NASDAQ: LIFE) today announced that its Applied Biosystems 7500 Fast Dx Real-Time PCR Instrument is available as a platform suitable for in vitro diagnostics (IVD) use in Europe. Clinical laboratories from 22 countries and European institutions that develop in vitro molecular diagnostic assays in oncology, genetic disease and infectious disease will now be able to leverage the instrument’s regulatory clearance to develop tests for clinical applications.

24 Mar 2010

Virginia-based medical practice implements CTT's pain therapy medical device

Competitive Technologies, Inc. announced that a premier physician oncology practice based in Virginia has begun using CTT's Calmare® Therapy pain therapy medical device to treat patients suffering from pain related to cancer, under the direction of several medical oncologists.

24 Mar 2010

Renowned leaders to discuss latest findings in early-stage drug development for cancer

When people think of cancer treatment, chemotherapy infusions, injections and pills often come to mind. These treatments result from extensive research and testing in drug development. But how does the process begin?

24 Mar 2010

Alnylam Pharmaceuticals earns $20M technology transfer payment from Takeda Pharmaceutical

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has earned a $20 million technology transfer payment from Takeda Pharmaceutical Company Limited as part of the strategic alliance the companies formed in May 2008.

23 Mar 2010

Aureus Pharma to participate in € 118 million BioIntelligence R&D programme

Aureus Pharma, a leading provider of knowledge management solutions to accelerate discovery in the life sciences industry, announces today it’s participation in a EUR118.2 million (USD 160 million) project. The project is the Biointelligence R&D programme designed to promote the use of systemic modeling and simulation tools to exploit biomedical databases to improve research efficiency.

23 Mar 2010

ChemGenex shares falter as FDA requests more data on new leukemia drug

ChemGenex Pharmaceuticals Ltd. Shares fell most in the last 16 years to AUD$0.44 following a concern raised by the US drug regulators – US FDA. The FDA requested on Monday for more uniform clinical test data before they review and consider approval of the company’s new leukemia drug.

23 Mar 2010

Ipsen, GTx expand partnership for toremifene 80 mg

Ipsen today announced the expansion of their partnership for the development and commercialization of toremifene 80 mg for the reduction of fractures in men with advanced prostate cancer on androgen deprivation therapy (ADT) and toremifene 20 mg for the prevention of prostate cancer in high risk patients with High Grade Prostatic Intraepithelial Neoplasia lesions (HGPIN).

23 Mar 2010

Short of specialists and cancer care

Associate Professor Bogda Koczwara, from the Medical Oncology Group of Australia, conducted the survey which found just 19 per cent of all those diagnosed with cancer were receiving chemotherapy.

23 Mar 2010

FDA approves APP Pharmaceuticals' Indomethacin for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Indomethacin for Injection. Indomethacin is therapeutically equivalent to the reference-listed drug INDOCIN® I.V., by Lundbeck, Inc.

23 Mar 2010

FDA's ODAC voted to review T315I mutation prior to approval of OMAPRO

ChemGenex Pharmaceuticals Limited announced today that the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee voted 7-1 that a validated test to identify the T315I mutation should be reviewed by the FDA prior to approval of OMAPRO™ (omacetaxine mepesuccinate).

23 Mar 2010

$CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval$

CTI's pixantrone trial for relapsed/refractory aggressive NHL: FDA ODAC finds data inadequate for approval

Cell Therapeutics, Inc. announced today that the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee panel voted unanimously that clinical trial data was not adequate to support approval of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

23 Mar 2010

Life Beyond Cancer Foundation launches new Web site to help cancer patients

The Life Beyond Cancer Foundation, formerly known as the US Oncology Foundation, announced today that it has launched its new Web site at www.lifebeyondcancer.org. Touting an array of resources for cancer patients throughout the United States, the foundation's mission is to help cancer patients and their families connect with financial assistance, support programs and other necessary resources that can help them on their cancer journey.

23 Mar 2010

GUMC scientists awarded five-year $7.5M grant to perfect treatment of breast cancer

Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center were awarded a five-year $7.5 million grant to tease apart - in the most comprehensive way ever devised -the role of a single protein receptor in breast cells in cancer development and treatment.

22 Mar 2010